Inarigivir (ORI-9020) (Synonyms: ORI-9020; SB-9000) |
Catalog No.GC32104 |
Inarigivir(ORI-9020)(ORI-9020)는 B형 간염 바이러스를 발현하는 형질전환 마우스에서 간 HBV DNA를 유의하게 감소시킬 수 있는 디뉴클레오티드 항바이러스제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 475650-36-3
Sample solution is provided at 25 µL, 10mM.
Inarigivir (ORI-9020;SB-9000) is a dinucleotide which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus.
I.p. injection of Inarigivir at 100 mg/kg/day significantly reduces viral DNA in the liver and shows anti-HBV activity similar ADV positive control. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values[1].
[1]. Iyer RP, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48(6):2318-20.
Average Rating: 5
(Based on Reviews and 15 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *